Novartis experimental drug for ALS fails, Bloomberg News reports
16/09/2026 16:13
Novartis experimental drug for ALS fails, Bloomberg News reports Sept 16 (Reuters) - Novartis NOVN.S halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig's disease, Bloomberg News reported on Wednesday.
The mid-stage trial was discontinued after the medicine failed to show it worked better than a dummy drug in delaying disease progression, Novartis confirmed in an emailed statement to Bloomberg.
(Reporting by Anusha Shah in Bengaluru; Editing by Vijay Kishore)
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant